NOXXON Pharma AG Announces Appointment of Lawrence E. Posner to Its Board of Directors

BERLIN--(BUSINESS WIRE)--NOXXON Pharma AG (NOXXON), developer of mirror image oligonucleotide therapeutics termed Spiegelmers®, announced today the appointment of Lawrence E. Posner, MD, to its Board of Directors.
MORE ON THIS TOPIC